Examining the Long-term Clinical Evidence of Therapies for Inflammatory Bowel Disease in Bio-naïve Patients : Episode 18
Key Takeaways and Prospective Treatment Advances
David Hudesman, MD, Maia Kayal, MD, Miguel Regueiro, MD, Anita Afzali, MD, and Millie Long summarize their discussion of Inflammatory Bowel Disease (IBD) and discuss prospective advances in treatment options.
EP: 1.Overview of IBD
EP: 2.Treatment Factors of IBD
EP: 3.Managing Care for IBD Patients Not Responding to Treatment
EP: 4.Selecting First-Line Treatments for CD
EP: 5.The Role of Vedolizumab and Risankizumab in CD
EP: 6.Efficacy and Safety of Ustekinumab for CD
EP: 7.Selecting Therapies for CD in Pregnancy
EP: 8.Selecting Treatments in Patients With EIM
EP: 9.Second-Line Therapies for CD
EP: 10.Optimizing Therapies for CD
EP: 11.Major Takeaways for Treating CD
EP: 12.Treatment Approaches for Patients With UC
EP: 13.The Role of Ozanimod in UC
EP: 14.The Role of Ustekinumab in UC
EP: 15.Utilizing JAK Inhibitors in Patients With UC
EP: 16.Treatment Sequencing for UC
EP: 17.Biosimilar Treatment Options for Patients With UC
Now Viewing
EP: 18.Key Takeaways and Prospective Treatment Advances
Related Videos
Related Content
